Jordan Ciuro, MD
@jordanciuro
Medical oncologist @WinshipAtEmory, specializing in genitourinary cancer. Editor and TB moderator @themednet.org
When is less treatment more in #mHSPC? 🔎Exploring the role of treatment de-escalation in oligometastatic hormone-sensitive prostate cancer Watch our latest video with Dr. Shahid Ahmed on GUOncologyNow⬇️ guoncologynow.com/post/when-less… @WinshipAtEmory @GUOncologyNow @TargetedOnc…
Thrilled to kick off the @ASCO Virtual Mentorship Program #VMP2025! Excited to learn, grow, and collaborate with amazing mentors @AndreaNecchi & @BrigidaMaiorano, and connect with inspiring peers worldwide - @imdat_eroglu @RF_Correa #SuleymanKarakeci #HalilbrahimEllez. Here's to…
Kick-off call for my @ASCO Virtual Mentorship Program #VMP 2025-26 class | it will be a fun journey with 5 mentees 🇹🇷🇲🇽🇺🇸 @imdat_eroglu @Rf_Correa @jordanciuro #SuleymanKarakeçi #HalilİbrahimEllez | @BrigidaMaiorano dropbox.com/scl/fi/mkfssgr…
🚨 Check out our new post in @ASCO Daily News 🔎Exploring emerging paradigms transforming metastatic hormone-sensitive prostate cancer care - from novel systemic therapies to personalized strategies. A shift in practice is underway!! @jberchuck @EHeath4100 & Dr. Brad Carthon…
Great time with @umangtalking discussing the current real world treatment patterns in metastatic hormone sensitive prostate cancer. Check out our 3 part series summary @GUOncologyNow and his current work: ascopubs.org/doi/10.1200/JC…
📺 In the first of a three-part series, @jordanciuro spoke with @umangtalking on the ongoing efforts to understand and reduce disparities in the real-world application of intensified therapy for #mHSPC: buff.ly/OUgoJo5 🔎 They explore future research directions,…
Thank you to the discussant Rahul Aggarwal and @jordanciuro for highlighting A-DREAM for treatment interruption for pts with PSA < 0.2 after 18-24 mo of ADT+ARPI, with primary endpoint of 18 months treatment-free with testosterone recovery. @DanaFarber_GU @bergsa83 @ALLIANCE_org
🔎Tailoring treatment in mCSPC w/ biomarkers? Evolving landscape beyond high vs low and synchronous vs metachronous disease @ASCO ✅PSA nadir is strongly prognostic in IRONMAN - pending trial data (TRIPLE-SWITCH and A-DREAM if PSA >/0.2) to guide nadir in therapy decisions…
🔎Carboplatin+Cabazitaxel+Cetrelimab (antiPD1) induction followed by Niraparib +/- Cetrelimab maintenance in aggressive variant pc (AVPC)? Ph2 C3NIRA trial ✅Combination therapy results in meaningful benefit in aggressive variant disease ➡️Treatment has substantial toxicity -…
🔎Olaparib + Radium223 vs Radium223 in mCRPC with bone metastasis? Ph2 COMRADE ✅Reduced dose olaparib +radium improved rPFS 8.9 vs 4.7m HR 0.47 ✅Most pronounced in pts w/o prior doce & </ 20 mets ✅ctDNA at C1D1 and C2D1 was prognostic @ASCO @oncoalert @Oncolive @TargetedOnc…
🔎Niraparib + Abiraterone in mCSPC with HRRm? AMPLITUDE ✅Met endpoint of rPFS; greatest benefit in BRCA alterations (rPFS BRCAm HR 0.52 vs HRRm ITT HR 0.63) ✅Safety was consistent with previous MAGNITUDE trial with <5% pts discontinuing treatment @ASCO @oncoalert @Oncolive…
🔎Tailoring treatment in mCSPC w/ biomarkers? Evolving landscape beyond high vs low and synchronous vs metachronous disease @ASCO ✅PSA nadir is strongly prognostic in IRONMAN - pending trial data (TRIPLE-SWITCH and A-DREAM if PSA >/0.2) to guide nadir in therapy decisions…
🔎5y follow up of OS of Enzalutamide + ADT in mHSPC? ARCHES trial ✅Enza + ADT had 66% probability of survival at 5y with reduction in risk of death by 30% despite substantial crossover ✅High-volume disease had longer OS at 3y then those on placebo+ADT; survival rate improved…
🔎HRQoL with Darolutamide in the ph3 ARANOTE trial? ✅Darolutamide confers a positive impact on HRQoL; meaningful delays in pain progression and deterioration HRQoL vs placebo in mHSPC @ASCO @oncoalert @Oncolive @TargetedOnc @OncoReporte @Urotoday #ASCO25 #genitourinarycancer…
🔎Transcriptome classification of PTEN inactivation to predict survival benefit from docetaxel at start of ADT for mPC? Ancillary study of STAMPEDE trials ✅PTEN inactivity associates with shorter survival following ADT+abiraterone & predicts sensitivity to docetaxel in mPC…
🔎Prognostic significance of PSA>0.2 after 6-12m txt for mHSPC with ARPI: IRONMAN registry (prospective international cohort >4600 pts with mPC) ✅PSA at 6-12m after ADT start is prognostic in mHSPC on ADT+ ARPI ✅PSA <0.2 (esp <0.1) at 6-12m has good prognosis; role of…
🔎What is predictive or prognostic value of baseline PSMA-PET total tumor volume (TTV) and SUVmean? Data from ANZUP1901 trial of enza vs enza +Lu-PSMA in mCRPC ✅TTV is prognostic for OS in men receiving enza ✅TTV is predictive for OS with addition of LuPSMA to enza ✖️SUVmean…
🔎Results of Terbium-161 PSMA radioligand therapy (attaches PSMA, Beta emitter w/ Auger electrons) in mCRPC: VIOLET trial ✅Low rate of toxicity (up to 7.4 GBq) w/ 7% G3-4 AE ✅PSA >/ 90% RR 40%, rPFS median 11.1m @ASCO @oncoalert @Oncolive @TargetedOnc @OncoReporte @Urotoday…
